Molecular modeling of the second extracellular loop of G‐protein coupled receptors and its implication on structure‐based virtual screening

The current study describes the validation of high‐throughput modeling procedures for the construction of the second extracellular loop (ecl2) of all nonolfactory human G Protein‐coupled receptors. Our modeling flowchart is based on the alignment of essential residues determining the particular ecl2 fold observed in the bovine rhodopsin (bRho) crystal structure. For a set of GPCR targets, the dopamine D2 receptor (DRD2), adenosine A3 receptor (AA3R), and the thromboxane A2 receptor (TA2R), the implications of including ecl2 atomic coordinates is evaluated in terms of structure‐based virtual screening accuracy: the suitability of the 3D models to distinguish between known antagonists and randomly chosen decoys using automated docking approaches. The virtual screening results of different models describing increasingly exhaustive receptor representations (seven helices only, seven helices and ecl2 loop, full model) have been compared. Explicit modeling of the ecl2 loop was found to be important in only one of three test cases whereas a loopless model was shown to be accurate enough in the two other receptors. An exhaustive comparison of ecl2 loops of 365 receptors to that of bRho suggests that explicit ecl2 loop modeling should be reserved to receptors where loop building can be guided by experimental restraints. Proteins 2008; 71:599–620. © 2007 Wiley‐Liss, Inc.

[1]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[2]  C. Davies,et al.  Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. , 2006, European journal of pharmacology.

[3]  H. Wikström,et al.  Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT. , 1999, Bioorganic & medicinal chemistry.

[4]  L. Naylor,et al.  Structural Studies on D2 Dopamine Receptors: Mutation of a Histidine Residue Specifically Affects the Binding of a Subgroup of Substituted Benzamide Drugs , 1994, Journal of neurochemistry.

[5]  Bernard Pirotte,et al.  From the design to the clinical application of thromboxane modulators. , 2006, Current pharmaceutical design.

[6]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[7]  J. Turek,et al.  Differential Mapping of the Amino Acids Mediating Agonist and Antagonist Coordination with the Human Thromboxane A2 Receptor Protein* , 2006, Journal of Biological Chemistry.

[8]  P. Pauwels,et al.  Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. , 1998, Molecular pharmacology.

[9]  Andreas Evers,et al.  Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.

[10]  Sergio A Hassan,et al.  Ab initio computational modeling of loops in G‐protein‐coupled receptors: Lessons from the crystal structure of rhodopsin , 2006, Proteins.

[11]  J. Pin,et al.  Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. , 2005, Journal of medicinal chemistry.

[12]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[13]  G. Bokoch,et al.  Binding of Low Affinity N-formyl Peptide Receptors to G Protein , 1995, The Journal of Biological Chemistry.

[14]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[15]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[16]  Kenneth A Jacobson,et al.  Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. , 2006, Journal of molecular graphics & modelling.

[17]  Thomas Lengauer,et al.  Lead Identification by Virtual Screening , 2007 .

[18]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt): an expanding universe of protein information , 2005, Nucleic Acids Res..

[19]  L. Audoly,et al.  The Second Extracellular Loop of the Prostaglandin EP3 Receptor Is an Essential Determinant of Ligand Selectivity* , 1997, The Journal of Biological Chemistry.

[20]  J. Bockaert,et al.  Molecular Characterization of a Purified 5-HT4 Receptor , 2005, Journal of Biological Chemistry.

[21]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[22]  Giampiero Spalluto,et al.  Progress in the pursuit of therapeutic adenosine receptor antagonists , 2006, Medicinal research reviews.

[23]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[24]  Pieter F. W. Stouten,et al.  Fast prediction and visualization of protein binding pockets with PASS , 2000, J. Comput. Aided Mol. Des..

[25]  E A Merritt,et al.  Raster3D Version 2.0. A program for photorealistic molecular graphics. , 1994, Acta crystallographica. Section D, Biological crystallography.

[26]  Krzysztof Palczewski,et al.  Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. , 2003, Biochemistry.

[27]  Didier Rognan,et al.  High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening , 2004, J. Chem. Inf. Model..

[28]  Didier Rognan,et al.  A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.

[29]  K. Marx,et al.  Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. , 1997, Biochemistry.

[30]  K. Jacobson,et al.  Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor* , 2002, The Journal of Biological Chemistry.

[31]  E. Meng,et al.  Rhodopsin Sees the Light , 2000, Science.

[32]  Thomas Lengauer,et al.  Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.

[33]  L. Naylor,et al.  Effect of Multiple Serine/Alanine Mutations in the Transmembrane Spanning Region V of the D2 Dopamine Receptor on Ligand Binding , 2000, Journal of neurochemistry.

[34]  J. Hwa,et al.  Clusters of transmembrane residues are critical for human prostacyclin receptor activation. , 2004, Biochemistry.

[35]  D. Rognan,et al.  Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors. , 2007, Molecular endocrinology.

[36]  Lei Shi,et al.  The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  John Hwa,et al.  The Unique Ligand-binding Pocket for the Human Prostacyclin Receptor , 2003, The Journal of Biological Chemistry.

[38]  Peter L. Freddolino,et al.  Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Yang Zhang,et al.  Structure Modeling of All Identified G Protein–Coupled Receptors in the Human Genome , 2006, PLoS Comput. Biol..

[40]  J. Ballesteros,et al.  A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.

[41]  T. Sakmar,et al.  Rhodopsin: structural basis of molecular physiology. , 2001, Physiological reviews.

[42]  K. Jacobson,et al.  Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. , 1994, The Journal of biological chemistry.

[43]  P. Kraulis A program to produce both detailed and schematic plots of protein structures , 1991 .

[44]  R. Hermosilla,et al.  The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues , 2000, FEBS letters.

[45]  Shay Bar-Haim,et al.  G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Teulon,et al.  Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. , 1993, Journal of medicinal chemistry.

[47]  D. Higgins,et al.  T-Coffee: A novel method for fast and accurate multiple sequence alignment. , 2000, Journal of molecular biology.

[48]  H. Perez,et al.  Human formyl peptide receptor ligand binding domain(s). Studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of receptor occupancy. , 1994, The Journal of biological chemistry.

[49]  J. Ballesteros,et al.  Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.

[50]  J. Wess,et al.  Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.

[51]  G. FitzGerald,et al.  Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. , 1993, Molecular pharmacology.

[52]  E. Green,et al.  Novel human α1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

[53]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[54]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[55]  J. Hwa,et al.  Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. , 2007, Prostaglandins & other lipid mediators.

[56]  E. Jaeger,et al.  Comparison of automated docking programs as virtual screening tools. , 2005, Journal of Medicinal Chemistry.

[57]  Structure. Rhodopsin sees the light. , 2000, Science.

[58]  Malin M. Young,et al.  Structure and dynamics of dark‐state bovine rhodopsin revealed by chemical cross‐linking and high‐resolution mass spectrometry , 2006, Protein science : a publication of the Protein Society.

[59]  Robert P Bywater,et al.  Location and nature of the residues important for ligand recognition in G‐protein coupled receptors , 2005, Journal of molecular recognition : JMR.

[60]  K. Jacobson,et al.  Nucleoside Modification and Concerted Mutagenesis of the Human A3 Adenosine Receptor to Probe Interactions Between the 2-Position of Adenosine Analogs and Gln167 in the Second Extracellular Loop , 2005, Nucleosides, nucleotides & nucleic acids.

[61]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[62]  K Ezumi,et al.  Computer-aided molecular modeling of a thromboxane receptor antagonist S-145 and its related compounds. , 1990, Journal of medicinal chemistry.

[63]  Michael G. Davis,et al.  Mutagenic Analysis of Platelet Thromboxane Receptor Cysteines , 1996, The Journal of Biological Chemistry.

[64]  D. Perez,et al.  Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. , 1996, Molecular pharmacology.

[65]  Stephen Hanessian,et al.  A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors. , 2006, Journal of medicinal chemistry.

[66]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[67]  D. Scholl,et al.  Serine and alanine mutagenesis of the nine native cysteine residues of the human A(1) adenosine receptor. , 2000, Biochemical pharmacology.

[68]  Kenneth A. Jacobson,et al.  The Role of Amino Acids in Extracellular Loops of the Human P2Y1 Receptor in Surface Expression and Activation Processes* , 1999, The Journal of Biological Chemistry.

[69]  P. Seeman Targeting the dopamine D2 receptor in schizophrenia , 2006, Expert opinion on therapeutic targets.

[70]  L. Audoly,et al.  A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. , 1998, European journal of pharmacology.

[71]  K. Ruan,et al.  A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor , 2005, BMC Biochemistry.

[72]  Luis Moroder,et al.  Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor. , 2005, Journal of medicinal chemistry.

[73]  Kurt Kristiansen,et al.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.

[74]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[75]  R. Graham,et al.  The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. , 1994, The Journal of biological chemistry.

[76]  Adam J Pawson,et al.  Irreversible activation of the gonadotropin-releasing hormone receptor by photoaffinity cross-linking: localization of attachment site to Cys residue in N-terminal segment. , 1997, Biochemistry.

[77]  K. Jacobson,et al.  Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. , 2001, Biochemical and biophysical research communications.

[78]  Marc Parmentier,et al.  The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* , 2003, The Journal of Biological Chemistry.

[79]  R. Jensen,et al.  Molecular basis of the selectivity of gastrin-releasing peptide receptor for gastrin-releasing peptide. , 2002, Molecular pharmacology.

[80]  Leonardo Pardo,et al.  An Activation Switch in the Rhodopsin Family of G Protein-coupled Receptors , 2005, Journal of Biological Chemistry.

[81]  H. Levine,et al.  Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. , 2004, Biochemistry.

[82]  K. Jacobson,et al.  Constitutive Activation of A3 Adenosine Receptors by Site-Directed Mutagenesis , 2001 .

[83]  J. Klco,et al.  Essential role for the second extracellular loop in C5a receptor activation , 2005, Nature Structural &Molecular Biology.

[84]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[85]  Lei Shi,et al.  The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.

[86]  Maya Topf,et al.  PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.

[87]  Robert H Mach,et al.  Synthesis and characterization of selective dopamine D2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[88]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[89]  J. Fozard,et al.  A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential. , 2005, Bioorganic & medicinal chemistry letters.

[90]  O. Kocy,et al.  Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists. , 1993, Journal of medicinal chemistry.

[91]  P. Pauwels,et al.  Coupling of Canine Serotonin 5‐HT1B and 5‐HT1D Receptor Subtypes to the Formation of Inositol Phosphates by Dual Interactions with Endogenous Gi/o and Recombinant Gα15 Proteins , 2000, Journal of neurochemistry.

[92]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[93]  M. P. Turpin,et al.  Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. , 1998, Journal of receptor and signal transduction research.

[94]  K. Jacobson,et al.  Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. , 2001, Journal of medicinal chemistry.

[95]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.